Filing summary
Entity and period: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-Q for the quarter and nine months ended December 31, 2015 (fiscal Q3 2016), not a filing for “Solana Co” or calendar Q3 2015. The interim financial statements are unaudited. Investors should verify the issuer and period before relying on this summary.
Business context
Helius is a development-stage medical technology company focused on its PoNS neuromodulation device. It reported no commercial product or service revenue in either the three or nine months ended December 31, 2015. Development, clinical and regulatory work remained necessary before commercialization.
Financial performance and position
| Metric | Three months ended Dec. 31, 2015 | Nine months ended Dec. 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | None | None | None |
| Operating expenses | $2.84 million | $6.40 million | $3.09 million / $7.24 million |
| Net loss | $2.40 million | $3.54 million | $2.48 million / $7.80 million |
| Basic loss per share | $0.04 | $0.05 | $0.04 / $0.14 |
| Cash used in operations | Not stated for the quarter | $6.25 million | $4.38 million |
Operating expenses declined year over year for the nine-month period, notably due to lower consulting and R&D expense, including lower share-based compensation in the prior-year comparison. The current-year net loss was also lower, helped by a $1.63 million non-cash gain from the change in fair value of derivative liabilities and foreign-exchange gains. In the three-month period, operating expenses and net loss were also lower than in 2014.
At December 31, 2015, cash and cash equivalents were $4.35 million, current assets $5.26 million, current liabilities $6.41 million, and working capital was negative $1.16 million. Total liabilities were $7.24 million, including an $830,378 derivative liability and a $5.0 million obligation to issue shares and warrants. The $2.0 million A&B convertible note had been converted into shares and warrants; the remaining $5.0 million commitment was drawn on December 29, with the securities delivered on January 7, 2016. No commercial gross margin was reported because there were no commercial sales.
Cash increased from $418,893 at March 31, 2015, largely reflecting $9.73 million of financing cash inflows, including $7.0 million of convertible financing and private placements. Operating activities used more cash than in the prior-year period. The filing states that management did not expect available resources to meet operating and capital needs for the ensuing fiscal year and that, without additional financing, resources were not expected to last through the third quarter of calendar 2016.
Material changes, outlook and risks
- Financing and dilution: The company entered a $7.0 million A&B funding arrangement. The $2.0 million initial note converted at $0.96 per unit; the remaining $5.0 million was funded at $0.90 per unit, with shares and warrants issued after quarter-end. The filing reports 66,637,653 shares outstanding at December 31 and 72,193,209 at February 16, 2016.
- Going concern: Management said cash resources were insufficient for the ensuing fiscal year, and the filing describes substantial doubt about the company’s ability to continue as a going concern. Further equity or debt financing was expected; availability and terms were uncertain. No quantified revenue or earnings guidance was provided.
- Product and regulatory execution: PoNS remained under development. FDA and Health Canada clearances, clinical evidence, manufacturing readiness, funding and commercial demand were not assured; the company disclosed it had not yet submitted regulatory clearance applications in the United States or Canada.
- Patent litigation: A prior consulting-related lawsuit was settled for €57,000 and dismissed without prejudice. Wicab’s earlier lawsuit was dismissed without prejudice, but Wicab later challenged the validity and inventorship of two patents; settlement discussions were ongoing, with possible U.S. Patent Office proceedings and potentially material consequences for the company’s intellectual property.
- Financial reporting controls and restatement: Disclosure controls were deemed ineffective as of December 31, 2015. A material weakness in accounting for non-employee share-based awards led to restatement of 2014 interim results. Management said remediation was ongoing; it also cited insufficient technical accounting expertise.
- Other notable items: The nine-month results included a $268,334 gain on extinguishment of debt, $845,146 of foreign-exchange gains and a $1.63 million derivative fair-value gain. These items are not equivalent to recurring operating performance or cash generation. The company also disclosed foreign-currency exposure and no hedging contracts.
Important facts for investors to verify
- Confirm the filing belongs to Helius Medical Technologies, Inc. and that December 31, 2015 is the intended reporting period; the request metadata names a different company and period.
- Review the post-quarter delivery of the 5,555,556 A&B shares and 2,777,778 warrants, and reconcile the resulting share count and dilution with the reported February 16 outstanding shares.
- Assess the company’s financing runway, financing terms and going-concern disclosures, given negative working capital and management’s stated funding shortfall.
- Track PoNS clinical and regulatory milestones, and any agreements or support from the U.S. Army, which the filing describes as uncertain.
- Monitor the Wicab patent dispute and its potential effect on the company’s rights to the PoNS technology.
- Review the restated 2014 comparisons and progress in remediating the material weakness. The cash-flow discussion gives operating cash use as both $6,254,526 and $6,254,529 in different passages; the financial statement reports $6,254,529.